Drug Profile
Research programme: apical sodium-dependent bile acid transporter inhibitors - Satiogen Pharmaceuticals
Latest Information Update: 05 Jan 2023
Price :
$50
*
At a glance
- Originator Satiogen Pharmaceuticals
- Class
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Primary sclerosing cholangitis
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2022 Pharmacodynamics data from the preclinical studies in primary sclerosing cholangitis presented at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2022)
- 23 May 2022 Satiogen Pharmaceuticals has been acquired by Mirum Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)